NCT07302087 Platelet Serotonin Deficiencies: the Strasbourg Experience
| NCT ID | NCT07302087 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Hemorrhagic Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-11-25 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-11-25 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hemorrhagic syndromes are investigated using algorithms established by reference centers and hemostasis societies. The investigation of platelet dense granules (nucleotide and serotonin testing) is part of the second-line tests. It can be performed in cases of platelet aggregation abnormalities in platelet-rich plasma (PRP) suggesting a secretion abnormality, or in cases where the latter is normal, it can be performed if the patient's clinical presentation points to a primary hemostasis abnormality and the clinician wishes to pursue further investigations Intraplatelet serotonin deficiencies are often iatrogenic and may be accompanied by bleeding. Their impact on platelet function is poorly documented.
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥ 18 years old) * Treated at Strasbourg University Hospital for a hemorrhagic syndrome, suggesting a primary hemostasis abnormality and normal von Willebrand factor, during the period from January 1, 2023, to April 1, 2024. Exclusion Criteria: \- Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07302087 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemorrhagic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07302087 currently recruiting?
Yes, NCT07302087 is actively recruiting participants. Contact the research team at dominique.desprez@chru-strasbourg.fr for enrollment information.
Where is the NCT07302087 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07302087 clinical trial?
NCT07302087 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 50 participants.